biostudies-literatureBrechet AMinisterstvo Zdravotnictví Ceské RepublikySwiss National Sciences Foundation8346https://www.ebi.ac.uk/biostudies/studies/S-EPMC11897124biostudies-literatureUnknown15(1)Tick-borne encephalitis virus (TBEV) infection can manifest as disease of variable severity, ranging from subclinical infection to severe disease with neurological involvement and potentially fatal outcome. Although TBE is recognized as a major public health problem in Europe, the true burden of disease is potentially underestimated. Here, we investigated TBEV-specific antibody prevalence, infection incidence, and seroreversion and antibody decline rates in a prospective Swiss healthcare worker (HCW) cohort. We screened serum samples from 1444 HCWs between June and October 2020, and from a subset again between August and September 2021, using a TBEV envelope (E) protein IgG ELISA. Positive samples underwent further analysis with a TBEV non-structural protein 1 (NS1) IgG ELISA, and seroconvScientific reportsTick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021.PMC11897124PZ00P3_179919NU21-05-00143Kohler PSalat JBrechet AFriedl ADorr TLienhard RVock MGrassli FCroxatto AAckermann-Gaumann RVuichard-Gysin DRuzek DfalseTick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021.Tick-borne encephalitis virus (TBEV) infection can manifest as disease of variable severity, ranging from subclinical infection to severe disease with neurological involvement and potentially fatal outcome. Although TBE is recognized as a major public health problem in Europe, the true burden of disease is potentially underestimated. Here, we investigated TBEV-specific antibody prevalence, infection incidence, and seroreversion and antibody decline rates in a prospective Swiss healthcare worker (HCW) cohort. We screened serum samples from 1444 HCWs between June and October 2020, and from a subset again between August and September 2021, using a TBEV envelope (E) protein IgG ELISA. Positive samples underwent further analysis with a TBEV non-structural protein 1 (NS1) IgG ELISA, and seroconv2025-01-01T00:00:00Z2025 Mar2025-04-04T09:07:21.746Z2025-04-04T09:07:21.746ZS-EPMC118971244006929010.1038/s41598-025-92560-1